Id |
Subject |
Object |
Predicate |
Lexical cue |
T0 |
0-8 |
POSREG |
denotes |
Elevated |
T1 |
9-19 |
MPA |
denotes |
expression |
T2 |
23-26 |
GENE |
denotes |
p53 |
T3 |
27-43 |
POSREG |
denotes |
gain-of-function |
T4 |
53-58 |
VAR |
denotes |
R175H |
T5 |
62-80 |
DISEASE |
denotes |
endometrial cancer |
T6 |
91-99 |
POSREG |
denotes |
increase |
T7 |
104-123 |
CPA |
denotes |
invasive phenotypes |
T8 |
127-137 |
POSREG |
denotes |
activation |
T9 |
145-166 |
PATHWAY |
denotes |
EGFR/PI3K/AKT pathway |
T10 |
180-183 |
GENE |
denotes |
p53 |
T11 |
205-212 |
VAR |
denotes |
mutated |
T12 |
238-251 |
DISEASE |
denotes |
human cancers |
T13 |
272-276 |
NEGREG |
denotes |
loss |
T14 |
280-306 |
MPA |
denotes |
tumor suppression function |
T15 |
311-319 |
POSREG |
denotes |
exertion |
T16 |
323-340 |
NEGREG |
denotes |
dominant-negative |
T17 |
395-398 |
GENE |
denotes |
p53 |
T18 |
399-406 |
VAR |
denotes |
mutants |
T19 |
411-415 |
POSREG |
denotes |
gain |
T20 |
422-441 |
MPA |
denotes |
oncogenic functions |
T21 |
443-459 |
POSREG |
denotes |
gain-of-function |
T22 |
461-464 |
POSREG |
denotes |
GOF |
T23 |
480-488 |
REG |
denotes |
regulate |
T24 |
496-507 |
CPA |
denotes |
development |
T25 |
512-523 |
CPA |
denotes |
progression |
T26 |
534-552 |
DISEASE |
denotes |
endometrial cancer |
T27 |
554-557 |
GENE |
denotes |
p53 |
T28 |
558-566 |
VAR |
denotes |
mutation |
T29 |
581-591 |
REG |
denotes |
associated |
T30 |
608-630 |
DISEASE |
denotes |
nonendometrioid cancer |
T31 |
659-662 |
GENE |
denotes |
p53 |
T32 |
663-670 |
VAR |
denotes |
mutants |
T33 |
671-682 |
REG |
denotes |
contributed |
T34 |
686-704 |
DISEASE |
denotes |
endometrial cancer |
T35 |
705-716 |
CPA |
denotes |
progression |
T36 |
729-732 |
POSREG |
denotes |
GOF |
T37 |
769-781 |
REG |
denotes |
relationship |
T38 |
790-800 |
MPA |
denotes |
expression |
T39 |
804-807 |
GENE |
denotes |
p53 |
T40 |
808-811 |
POSREG |
denotes |
GOF |
T41 |
812-820 |
VAR |
denotes |
mutation |
T42 |
822-831 |
VAR |
denotes |
p53-R175H |
T43 |
837-855 |
CPA |
denotes |
invasive potential |
T44 |
865-883 |
DISEASE |
denotes |
endometrial cancer |
T45 |
925-938 |
POSREG |
denotes |
up-regulation |
T46 |
943-958 |
NEGREG |
denotes |
down-regulation |
T47 |
962-971 |
VAR |
denotes |
p53-R175H |
T48 |
988-996 |
POSREG |
denotes |
inducing |
T49 |
997-1006 |
VAR |
denotes |
p53-R175H |
T50 |
1028-1039 |
NEGREG |
denotes |
suppressing |
T51 |
1044-1047 |
GENE |
denotes |
p53 |
T52 |
1100-1106 |
POSREG |
denotes |
forced |
T53 |
1107-1122 |
POSREG |
denotes |
over-expression |
T54 |
1126-1135 |
VAR |
denotes |
p53-R175H |
T55 |
1150-1158 |
POSREG |
denotes |
promoted |
T56 |
1164-1173 |
CPA |
denotes |
migration |
T57 |
1178-1186 |
CPA |
denotes |
invasion |
T58 |
1192-1199 |
POSREG |
denotes |
induced |
T59 |
1200-1210 |
POSREG |
denotes |
activation |
T60 |
1218-1306 |
PATHWAY |
denotes |
epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway |
T61 |
1320-1331 |
NEGREG |
denotes |
suppression |
T62 |
1382-1391 |
NEGREG |
denotes |
inhibited |
T63 |
1397-1406 |
CPA |
denotes |
migration |
T64 |
1411-1419 |
CPA |
denotes |
invasion |
T65 |
1425-1433 |
REG |
denotes |
resulted |
T66 |
1437-1448 |
NEGREG |
denotes |
attenuation |
T67 |
1452-1473 |
PATHWAY |
denotes |
EGFR/PI3K/AKT pathway |
T68 |
1531-1539 |
POSREG |
denotes |
elevated |
T69 |
1540-1550 |
MPA |
denotes |
expression |
T70 |
1581-1597 |
POSREG |
denotes |
gain-of-function |
T71 |
1598-1606 |
MPA |
denotes |
activity |
T72 |
1610-1618 |
POSREG |
denotes |
activate |
T73 |
1623-1644 |
PATHWAY |
denotes |
EGFR/PI3K/AKT pathway |
T74 |
1658-1668 |
REG |
denotes |
contribute |
T75 |
1676-1694 |
CPA |
denotes |
invasive phenotype |
T76 |
1698-1716 |
DISEASE |
denotes |
endometrial cancer |
R0 |
T0 |
T3 |
CauseOf |
Elevated,gain-of-function |
R1 |
T0 |
T6 |
CauseOf |
Elevated,increase |
R10 |
T5 |
T3 |
ThemeOf |
endometrial cancer,gain-of-function |
R11 |
T5 |
T4 |
ThemeOf |
endometrial cancer,R175H |
R12 |
T8 |
T6 |
CauseOf |
activation,increase |
R13 |
T7 |
T6 |
ThemeOf |
invasive phenotypes,increase |
R14 |
T9 |
T8 |
ThemeOf |
EGFR/PI3K/AKT pathway,activation |
R15 |
T10 |
T11 |
ThemeOf |
p53,mutated |
R16 |
T12 |
T11 |
ThemeOf |
human cancers,mutated |
R17 |
T11 |
T13 |
CauseOf |
mutated,loss |
R18 |
T11 |
T15 |
CauseOf |
mutated,exertion |
R19 |
T14 |
T13 |
ThemeOf |
tumor suppression function,loss |
R2 |
T0 |
T8 |
CauseOf |
Elevated,activation |
R20 |
T17 |
T18 |
ThemeOf |
p53,mutants |
R21 |
T18 |
T13 |
CauseOf |
mutants,loss |
R22 |
T18 |
T15 |
CauseOf |
mutants,exertion |
R23 |
T18 |
T19 |
CauseOf |
mutants,gain |
R24 |
T18 |
T21 |
CauseOf |
mutants,gain-of-function |
R25 |
T18 |
T22 |
CauseOf |
mutants,GOF |
R26 |
T18 |
T23 |
CauseOf |
mutants,regulate |
R27 |
T20 |
T19 |
ThemeOf |
oncogenic functions,gain |
R28 |
T24 |
T23 |
ThemeOf |
development,regulate |
R29 |
T25 |
T23 |
ThemeOf |
progression,regulate |
R3 |
T1 |
T0 |
ThemeOf |
expression,Elevated |
R30 |
T26 |
T29 |
ThemeOf |
endometrial cancer,associated |
R31 |
T27 |
T28 |
ThemeOf |
p53,mutation |
R32 |
T28 |
T29 |
CauseOf |
mutation,associated |
R33 |
T30 |
T29 |
ThemeOf |
nonendometrioid cancer,associated |
R34 |
T31 |
T32 |
ThemeOf |
p53,mutants |
R35 |
T32 |
T33 |
CauseOf |
mutants,contributed |
R36 |
T32 |
T35 |
CauseOf |
mutants,progression |
R37 |
T32 |
T36 |
CauseOf |
mutants,GOF |
R38 |
T34 |
T33 |
ThemeOf |
endometrial cancer,contributed |
R39 |
T34 |
T35 |
ThemeOf |
endometrial cancer,progression |
R4 |
T2 |
T1 |
ThemeOf |
p53,expression |
R40 |
T34 |
T36 |
ThemeOf |
endometrial cancer,GOF |
R41 |
T35 |
T33 |
ThemeOf |
progression,contributed |
R42 |
T35 |
T36 |
ThemeOf |
progression,GOF |
R43 |
T38 |
T37 |
ThemeOf |
expression,relationship |
R44 |
T38 |
T40 |
ThemeOf |
expression,GOF |
R45 |
T39 |
T37 |
ThemeOf |
p53,relationship |
R46 |
T39 |
T38 |
ThemeOf |
p53,expression |
R47 |
T39 |
T41 |
ThemeOf |
p53,mutation |
R48 |
T41 |
T40 |
CauseOf |
mutation,GOF |
R49 |
T42 |
T38 |
ThemeOf |
p53-R175H,expression |
R5 |
T4 |
T3 |
CauseOf |
R175H,gain-of-function |
R50 |
T42 |
T41 |
ThemeOf |
p53-R175H,mutation |
R51 |
T44 |
T37 |
ThemeOf |
endometrial cancer,relationship |
R52 |
T44 |
T38 |
ThemeOf |
endometrial cancer,expression |
R53 |
T44 |
T40 |
ThemeOf |
endometrial cancer,GOF |
R54 |
T44 |
T43 |
ThemeOf |
endometrial cancer,invasive potential |
R55 |
T44 |
T45 |
ThemeOf |
endometrial cancer,up-regulation |
R56 |
T47 |
T46 |
ThemeOf |
p53-R175H,down-regulation |
R57 |
T50 |
T48 |
CauseOf |
suppressing,inducing |
R58 |
T51 |
T50 |
ThemeOf |
p53,suppressing |
R59 |
T52 |
T55 |
CauseOf |
forced,promoted |
R6 |
T4 |
T6 |
CauseOf |
R175H,increase |
R60 |
T52 |
T58 |
CauseOf |
forced,induced |
R61 |
T53 |
T55 |
CauseOf |
over-expression,promoted |
R62 |
T53 |
T58 |
CauseOf |
over-expression,induced |
R63 |
T54 |
T53 |
ThemeOf |
p53-R175H,over-expression |
R64 |
T54 |
T58 |
CauseOf |
p53-R175H,induced |
R65 |
T56 |
T55 |
ThemeOf |
migration,promoted |
R66 |
T57 |
T55 |
ThemeOf |
invasion,promoted |
R67 |
T60 |
T58 |
ThemeOf |
epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway,induced |
R68 |
T60 |
T59 |
ThemeOf |
epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway,activation |
R69 |
T61 |
T62 |
CauseOf |
suppression,inhibited |
R7 |
T4 |
T8 |
CauseOf |
R175H,activation |
R70 |
T61 |
T65 |
CauseOf |
suppression,resulted |
R71 |
T61 |
T66 |
CauseOf |
suppression,attenuation |
R72 |
T63 |
T62 |
ThemeOf |
migration,inhibited |
R73 |
T64 |
T62 |
ThemeOf |
invasion,inhibited |
R74 |
T67 |
T66 |
ThemeOf |
EGFR/PI3K/AKT pathway,attenuation |
R75 |
T68 |
T70 |
CauseOf |
elevated,gain-of-function |
R76 |
T68 |
T72 |
CauseOf |
elevated,activate |
R77 |
T68 |
T74 |
CauseOf |
elevated,contribute |
R78 |
T69 |
T68 |
ThemeOf |
expression,elevated |
R79 |
T73 |
T72 |
ThemeOf |
EGFR/PI3K/AKT pathway,activate |
R8 |
T5 |
T0 |
ThemeOf |
endometrial cancer,Elevated |
R80 |
T75 |
T74 |
ThemeOf |
invasive phenotype,contribute |
R81 |
T76 |
T74 |
ThemeOf |
endometrial cancer,contribute |
R82 |
T76 |
T75 |
ThemeOf |
endometrial cancer,invasive phenotype |
R9 |
T5 |
T1 |
ThemeOf |
endometrial cancer,expression |